d*******e
发帖数: 110 | 1 听说Yang Xu博士在国内开了个生物医药公司，搞得风生水起，简历上还写着：1980年
考入浙江大学医学院临床医学专业学习，1985年毕业于医学院获学士学位。
1990年考入美国康奈尔大学医学院肿瘤分子生物学专业学习，1994年毕业于美国康奈尔
大学医学院获博士学位；1995年1月～2000年1月：在美国史隆凯特林肿瘤研究所担任研
究员、教授，他与指导老师一起
在国际上首次创立人类单克隆抗体-CD33，该抗体也是美国FDA首次批准的白血病治疗药
物。如果是真的话，挺牛的。 | M*****n
发帖数: 16729 | 2 抗体治病，慢慢的，就效果就下降了
因为人体会产生中和性抗体的。 | d*******e
发帖数: 110 | 3 但是现在humanized MAb 还是有市场的，也赚钱。从效果上看，对癌症的治疗还是不错
的。 | e********s
发帖数: 93 | 4 I am not sure about the source of that resume, but it might potentially get Dr.Xu into some troubles:)
Dr. Xu was a student/postdoc in David Scheinberg's lab at Cornell/Sloan
Kettering, but I don't think he ever got a faculty position there. Dr.Xu might have made some contribution to the CD33 projects, his main work was about the regulation of CD13/aminopeptidase N.
While David's work has pushed Lintuzumab (humanized monoclonal antibody
against CD33) into several clinical tests, trials for AML were abandoned in 2010 when a phase IIb trial failed to show increased survival. There is another trial going on for lintuzumab in conjunction with bortezomib as a treatment of myelodysplastic syndromes.
As far as I know, the first monoclonal antibody against CD33 that got
approved by the FDA for treating leukemia is Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg), a monoclonal antibody to CD33 linked to a cytotoxic agent from the class of calicheamicins. To the best of my knowledge, the drug was developed at the Fred Hutchinson Cancer Research Center and I don't think Dr.Xu was involved in that project. Mylotarg was approved by the FDA in 2000 for use mainly in AML patients over the age of 60. Unfortunately it has brought up many serious safety concerns, and Pfizer had to withdraw the drug from market last year at FDA's request when a clinical trial showed "the drug increased patient death and added no benefit over conventional cancer therapies". |
|
